Compare CCLD & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | RANI |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | 3650 | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 126.8M |
| IPO Year | N/A | 2021 |
| Metric | CCLD | RANI |
|---|---|---|
| Price | $2.29 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 669.6K | ★ 874.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | $11.49 | $274.77 |
| Revenue Next Year | $7.95 | $79.44 |
| P/E Ratio | $32.04 | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $1.98 | $0.39 |
| 52 Week High | $4.01 | $3.87 |
| Indicator | CCLD | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 54.54 |
| Support Level | $2.22 | $0.46 |
| Resistance Level | $3.14 | $1.10 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 21.43 | 69.27 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.